The expression levels of T-cell markers, such as CD28 and CD3 epsilon, were not affected by the risk haplotypes, so the expression reduction in TRPC6 and other genes involved in T-cell activation was not due to the absence of T-cells within the tumor. This evidence concerns the gene TRPC6 and neoplasm.